title: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
authors.affiliation: American Society of Clinical Oncology, Cancer Policy and Clinical Affairs Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Temin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D013629:Tamoxifen; D017313:Fenretinide; D020849:Raloxifene Hydrochloride